미국 · 보도자료 · Esperion Therapeutics, Inc. · 2026-10-07 12:00
에스페리온, 넥스레톨·넥슬리젯 복제약 2040년 4월 전 출시 금지 합의
ANN ARBOR, Mich., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Esperion, a company wholly-owned by ARCHIMED, today announced that it has entered into a settlement agreement with Renata Limited (along with an affiliate). This agreement resolves the patent litigation brought by Esperion against Renata in response to Renata’s Abbreviated New Drug Applications (ANDAs) seeking approval to market generic versions
Esperion Therapeutics, Inc. 다른 공시·급등 이유 보기 · GK의 공시레이더 — 미국·한국 실시간 공시
